UKBi006-A
iLB-C-35m-r1, LB-35-1
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | UKBi006-A |
| Alternative name(s) |
iLB-C-35m-r1, LB-35-1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi011-A (NP0040-8) UKKi012-A (NP0041-17, NP0041) UKBi002-A (iLB-C2-36m-r2) UKBi004-A (LB-30-12, iLB-C1-30m-r12) RBi001-A (fb101, RB101) HUBi001-A (HUB001Ai) UOXFi005-A (JR053-1, SAMEA4453899) UOXFi006-A (OX2-28) UKKi020-A (NP0100-4) UKKi021-A (NP0105-2) UKKi020-B (NP0100-8) UKKi021-B (NP0105-19) UKKi020-C (NP0100-10E) UKKi020-D (NP0100-11) UKBi005-A (iLB-C-31f-r1, LB-31-1) EDi002-A (NAS2) UKKi022-A (NP0106-34) BIONi037-A (16423 ApoE3/3 (control line)) UKKi022-C (NP0106-10A) UKKi022-D (NP0106-5) UKBi003-A (iLB-MJD1-32m-r9, LB-32-r9) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Spinocerebellar ataxia type 3 UKBi008-A (iLB-MJD4-34m-r1, LB-34-1) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Spinocerebellar ataxia type 3 WTSIi002-A (HPSI0913i-eika_2) WTSIi004-A (HPSI1113i-qolg_3) WTSIi006-A (HPSI1113i-hayt_1) WTSIi008-A (HPSI1013i-kuxp_1) WTSIi010-A (HPSI0314i-xugn_1) WTSIi013-A (HPSI0214i-kucg_2) WTSIi014-A (HPSI0214i-heja_2) WTSIi016-A (HPSI0114i-oevr_3) WTSIi018-A (HPSI0114i-kolf_3) WTSIi019-A (HPSI0114i-iisa_3) BIONi010-A (K1P53) BIONi010-B (K2P53, BIONi010-B) BIONi010-C (BIONi010-C, K3P53) WTSIi022-A (HPSI1013i-yemz_1) WTSIi023-A (HPSI0114i-zapk_3) WTSIi025-A (HPSI1013i-pamv_1) |
Provider |
|
| Depositor | Universitätsklinikum Bonn (UKB) |
| Owner | Universitätsklinikum Bonn |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
Institut für Rekonstruktive Neurobiologie
Scottish Centre for Regenerative Medicine
|
| Derivation country | Germany |
External Databases |
|
| hPSCreg | UKBi006-A |
| BioSamples | SAMEA2590936 |
| Cellosaurus | CVCL_1E86 |
| ECACC | 66540004 |
| CLO | CLO_0100862 |
| Wikidata | Q54990265 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information#
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 30-34 |
| Ethnicity | Caucasian, German |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA2590892 |
hIPSC Derivation#
General |
|
| Source cell type |
fibroblast of dermis |
| Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
|
| Age of donor (at collection) | 30-34 |
| Collected in | 2008 |
| Passage number reprogrammed | P4 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Yes |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-3 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| TRA 1-81 |
Yes |
Morphology pictures
Differentiation Potency
In vivo teratoma
In vitro directed differentiation
Morphology
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|